NARESH P SINGH MD
Prescription History 1790721116
Internal Medicine - Pulmonary Disease in Las Vegas, NV


Quality Rating: 63.93 out of 100 score

NPI Status: Active since June 22, 2006

Contact Information

2000 WELLNESS WAY
LAS VEGAS, NV
ZIP 89106
Phone: (702) 384-5101
Fax: (702) 387-0104

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for NARESH P SINGH MD, an active Pulmonary Disease specialist practicing in Las Vegas, NV. Our medical registry currently tracks 44 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 3,129 documented patient claims. Among these therapy options, the most frequently utilized medication is Albuterol Sulfate Hfa, which accounts for 369 claims alone.


Adempas

Generic Formulation: RiociguatSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 674
NV State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills46.9
Peer Average Days Supply1,366
Conservative Utilization

This provider writes prescriptions for this formulation 48.9% less frequently than the standard regional baseline metric for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $310,245.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,488.91

State Avg Cost Per Claim

$12,873.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Riociguat is used to treat high blood pressure in the lungs (pulmonary hypertension). It can also be used to treat a certain type of high blood pressure in the lungs caused by blood clots (chronic thromboembolic pulmonary hypertension) when surgery has not been fully successful or is impossible. Riociguat works by relaxing and widening the blood vessels in your lungs so blood can flow more easily. Decreasing high blood pressure in the lungs allows your heart and lungs to work better and improves your ability to exercise.

Advair Diskus

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 23.0
Days Supply 690
NV State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills32.0
Peer Average Days Supply955
Conservative Utilization

This provider writes prescriptions for this formulation 28.6% less frequently than the standard regional baseline metric for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,631.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$708.76

State Avg Cost Per Claim

$623.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Advair Hfa

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 34.0
Days Supply 1,020
NV State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills29.9
Peer Average Days Supply894
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,923.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$995.72

State Avg Cost Per Claim

$605.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 369
30-Day Fills 434.6
Days Supply 9,886
NV State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills72.8
Peer Average Days Supply1,839
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 558.9% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,007.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.25

State Avg Cost Per Claim

$50.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Ambrisentan

Generic Formulation: AmbrisentanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 870
NV State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills27.1
Peer Average Days Supply813
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $127,942.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,411.82

State Avg Cost Per Claim

$3,871.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ambrisentan is used to treat high blood pressure in the lungs (pulmonary arterial hypertension). This condition is thought to be caused by increased levels of a certain natural substance (endothelin-1). This medication blocks the effects of endothelin-1, thereby helping to decrease the blood pressure in the lungs, slow the worsening of symptoms, and improve your ability to exercise.

Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 94
NV State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.6
Peer Average Days Supply236
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.8% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $69.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.76

State Avg Cost Per Claim

$13.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Atrovent Hfa

Generic Formulation: Ipratropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 27
30-Day Fills 30.0
Days Supply 775
NV State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills16.9
Peer Average Days Supply477
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 92.9% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,229.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$564.05

State Avg Cost Per Claim

$569.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Therapeutic Applications

Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.

Azelastine Hcl

Generic Formulation: Azelastine HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 43
30-Day Fills 72.6
Days Supply 2,110
NV State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills62.4
Peer Average Days Supply1,809
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,649.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$38.35

State Avg Cost Per Claim

$41.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing, and post-nasal drip caused by allergies or other conditions. Azelastine belongs to a class of drugs known as antihistamines. It works by blocking certain natural substances called histamines that are responsible for nasal symptoms.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 125
30-Day Fills 130.3
Days Supply 1,645
NV State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills38.0
Peer Average Days Supply227
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 237.8% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $981.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.85

State Avg Cost Per Claim

$8.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 137
30-Day Fills 184.0
Days Supply 5,520
NV State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills47.6
Peer Average Days Supply1,422
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 302.9% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $78,232.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$571.04

State Avg Cost Per Claim

$554.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 127
30-Day Fills 153.0
Days Supply 4,560
NV State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills62.3
Peer Average Days Supply1,865
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 170.2% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $103,082.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$811.68

State Avg Cost Per Claim

$834.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Cefuroxime

Generic Formulation: Cefuroxime AxetilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 69
30-Day Fills 69.0
Days Supply 568
NV State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.5
Peer Average Days Supply227
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 165.4% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $845.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.25

State Avg Cost Per Claim

$23.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cephalosporin antibiotic.

Therapeutic Applications

Cefuroxime is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 44
30-Day Fills 44.0
Days Supply 331
NV State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills29.5
Peer Average Days Supply429
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 63.0% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $332.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.56

State Avg Cost Per Claim

$22.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Doxycycline Monohydrate

Generic Formulation: Doxycycline MonohydrateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 46
30-Day Fills 46.0
Days Supply 400
NV State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills32.0
Peer Average Days Supply487
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 58.6% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $892.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.41

State Avg Cost Per Claim

$24.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A plant family of the order Dipsacales, subclass Asteridae, class Magnoliopsida. Members of this family are sometimes classified in CAPRIFOLIACEAE.

Therapeutic Applications

This medication is used to treat a certain type of skin condition called rosacea. It helps to reduce the number of pimples and bumps on the face, but it may not decrease redness. It works by reducing skin inflammation caused by rosacea. Although doxycycline belongs to the class of antibiotics known as tetracyclines, this product does not work as an antibiotic because it does not stop the growth of bacteria. Do not use this product to treat any infection, including viral infections (such as the common cold, flu). Use this medication only as prescribed by your doctor.

Eliquis

Generic Formulation: ApixabanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 21.0
Days Supply 630
NV State Average Benchmarks
Peer Average Claims65.0
Peer Average 30-Day Fills110.1
Peer Average Days Supply3,150
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.8% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,841.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$755.36

State Avg Cost Per Claim

$881.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Esbriet

Generic Formulation: PirfenidoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NV State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills25.2
Peer Average Days Supply755
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $44,723.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,726.96

State Avg Cost Per Claim

$11,276.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.

Flovent Diskus

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NV State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills15.1
Peer Average Days Supply452
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,655.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$221.31

State Avg Cost Per Claim

$261.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 44
30-Day Fills 92.0
Days Supply 2,760
NV State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills91.5
Peer Average Days Supply2,734
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $712.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.19

State Avg Cost Per Claim

$17.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone-Salmeterol

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 84
30-Day Fills 123.0
Days Supply 3,690
NV State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills29.9
Peer Average Days Supply895
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 342.1% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,240.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$288.58

State Avg Cost Per Claim

$250.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Furosemide

Generic Formulation: FurosemideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 22
30-Day Fills 36.3
Days Supply 976
NV State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills122.6
Peer Average Days Supply3,588
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.7% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$0.98

State Avg Cost Per Claim

$6.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.

Therapeutic Applications

Furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. This drug is also used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Furosemide is a water pill (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

Glassia

Generic Formulation: Alpha-1-Proteinase InhibitorSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 364
NV State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.0
Peer Average Days Supply364
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $227,869.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,528.44

State Avg Cost Per Claim

$7,664.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Plasma glycoprotein member of the serpin superfamily which inhibits TRYPSIN; NEUTROPHIL ELASTASE; and other PROTEOLYTIC ENZYMES.

Therapeutic Applications

This medication is used to treat lung problems (emphysema) caused by a certain inherited disease (alpha-1-proteinase inhibitor deficiency). In people with this condition, lung damage is caused by elastase, a natural substance that the body needs to kill bacteria in the lungs. Normally, a protein (alpha-1-proteinase inhibitor) stops elastase from working when it is no longer needed. However, in people who do not make enough of this protein, elastase does not stop working and damages the lungs. This medication replaces the missing alpha-1-proteinase inhibitor and helps to prevent further lung damage.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 33
30-Day Fills 35.0
Days Supply 1,050
NV State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills31.0
Peer Average Days Supply904
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 43.5% more claims than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,350.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$404.55

State Avg Cost Per Claim

$489.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Methylprednisolone

Generic Formulation: MethylprednisoloneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 51
30-Day Fills 51.0
Days Supply 315
NV State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills34.6
Peer Average Days Supply233
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 50.0% more claims than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $283.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.57

State Avg Cost Per Claim

$9.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A PREDNISOLONE derivative with similar anti-inflammatory action.

Therapeutic Applications

Methylprednisolone is used to treat conditions such as arthritis, blood disorders, severe allergic reactions, certain cancers, eye conditions, skin/kidney/intestinal/lung diseases, and immune system disorders. It decreases your immune system's response to various diseases to reduce symptoms such as swelling, pain, and allergic-type reactions. This medication is a corticosteroid hormone. Methylprednisolone may also be used with other medications in hormone disorders.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 167
30-Day Fills 455.0
Days Supply 13,650
NV State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills128.2
Peer Average Days Supply3,835
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 221.2% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,087.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.50

State Avg Cost Per Claim

$16.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Ofev

Generic Formulation: Nintedanib EsylateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 122
30-Day Fills 122.0
Days Supply 3,660
NV State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills40.2
Peer Average Days Supply1,202
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 212.8% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,640,982.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,450.67

State Avg Cost Per Claim

$12,685.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease.

Omeprazole

Generic Formulation: OmeprazoleSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 59
30-Day Fills 104.0
Days Supply 3,075
NV State Average Benchmarks
Peer Average Claims81.0
Peer Average 30-Day Fills205.0
Peer Average Days Supply6,127
Conservative Utilization

This provider writes prescriptions for this formulation 27.2% less frequently than the standard regional baseline metric for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $665.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.28

State Avg Cost Per Claim

$14.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Therapeutic Applications

Omeprazole is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and cough. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Omeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs). If you are self-treating with this medication, over-the-counter omeprazole products are used to treat frequent heartburn (occurring 2 or more days a week). Since it may take 1 to 4 days to have full effect, these products do not relieve heartburn right away. For over-the-counter products, carefully read the package instructions to make sure the product is right for you. Check the ingredients on the label even if you have used the product before. The manufacturer may have changed the ingredients. Also, products with similar brand names may contain different ingredients meant for different purposes. Taking the wrong product could harm you.

Opsumit

Generic Formulation: MacitentanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 96
30-Day Fills 96.0
Days Supply 2,880
NV State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills53.8
Peer Average Days Supply1,606
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 84.6% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,238,044.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,896.30

State Avg Cost Per Claim

$12,166.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Macitentan is used to treat high blood pressure in the lungs (pulmonary arterial hypertension). This condition is thought to be caused by increased levels of a certain natural substance (endothelin-1). This medication blocks the effects of endothelin-1, which helps decrease the blood pressure in the lungs, and reduces the risk of worsening of symptoms and hospital stays due to the disease.

Orenitram Er

Generic Formulation: Treprostinil DiolamineSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 324
NV State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.0
Peer Average Days Supply819
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.3% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $28,472.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,588.41

State Avg Cost Per Claim

$14,188.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a type of high blood pressure in the lungs (pulmonary arterial hypertension). Treprostinil helps to delay disease worsening and increase your ability to exercise. It works by relaxing and widening the blood vessels (arteries) in the lungs and other parts of the body so that blood can flow more easily. This medication belongs to a class of drugs known as vasodilators.

Pantoprazole Sodium

Generic Formulation: Pantoprazole SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 30.0
Days Supply 900
NV State Average Benchmarks
Peer Average Claims57.0
Peer Average 30-Day Fills130.8
Peer Average Days Supply3,885
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 78.9% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $107.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.94

State Avg Cost Per Claim

$15.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.

Therapeutic Applications

Pantoprazole is used to treat certain stomach and esophagus problems (such as acid reflux). It works by decreasing the amount of acid your stomach makes. This medication relieves symptoms such as heartburn, difficulty swallowing, and cough. It helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Pantoprazole belongs to a class of drugs known as proton pump inhibitors (PPIs).

Pirfenidone

Generic Formulation: PirfenidoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 39
30-Day Fills 39.0
Days Supply 1,168
NV State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.8
Peer Average Days Supply532
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 129.4% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $59,236.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,518.89

State Avg Cost Per Claim

$6,270.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 325
30-Day Fills 400.5
Days Supply 11,469
NV State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills51.9
Peer Average Days Supply884
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 673.8% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,747.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.38

State Avg Cost Per Claim

$5.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Prolastin C

Generic Formulation: Alpha-1-Proteinase InhibitorSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 117
30-Day Fills 119.7
Days Supply 3,360
NV State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills30.2
Peer Average Days Supply845
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 303.4% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,281,097.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,949.55

State Avg Cost Per Claim

$13,362.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Plasma glycoprotein member of the serpin superfamily which inhibits TRYPSIN; NEUTROPHIL ELASTASE; and other PROTEOLYTIC ENZYMES.

Therapeutic Applications

This medication is used to treat lung problems (emphysema) caused by a certain inherited disease (alpha-1-proteinase inhibitor deficiency). In people with this condition, lung damage is caused by elastase, a natural substance that the body needs to kill bacteria in the lungs. Normally, a protein (alpha-1-proteinase inhibitor) stops elastase from working when it is no longer needed. However, in people who do not make enough of this protein, elastase does not stop working and damages the lungs. This medication replaces the missing alpha-1-proteinase inhibitor and helps to prevent further lung damage.

Roflumilast

Generic Formulation: RoflumilastSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 33
30-Day Fills 58.0
Days Supply 1,713
NV State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills24.4
Peer Average Days Supply732
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 153.8% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,198.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$187.84

State Avg Cost Per Claim

$361.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Sildenafil Citrate

Generic Formulation: Sildenafil CitrateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 65
30-Day Fills 97.0
Days Supply 2,878
NV State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills35.7
Peer Average Days Supply949
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 160.0% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,674.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.76

State Avg Cost Per Claim

$20.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.

Therapeutic Applications

Sildenafil is used to treat high blood pressure in the lungs (pulmonary hypertension). It works by relaxing and widening the blood vessels in your lungs which allows the blood to flow more easily. Decreasing high blood pressure in the lungs allows your heart and lungs to work better and improves your ability to exercise. This medication is not recommended for use in children. Discuss the risks and benefits of this medication with the doctor.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 122
30-Day Fills 161.0
Days Supply 4,815
NV State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills45.6
Peer Average Days Supply1,367
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 293.5% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $88,395.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$724.56

State Avg Cost Per Claim

$730.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 37
30-Day Fills 57.0
Days Supply 1,710
NV State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills44.9
Peer Average Days Supply1,341
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $28,095.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$759.34

State Avg Cost Per Claim

$700.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 134
30-Day Fills 207.0
Days Supply 6,210
NV State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills44.8
Peer Average Days Supply1,344
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 362.1% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $85,334.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$636.82

State Avg Cost Per Claim

$585.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Tadalafil

Generic Formulation: TadalafilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 34
30-Day Fills 40.0
Days Supply 1,185
NV State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills44.6
Peer Average Days Supply1,331
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,885.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$908.41

State Avg Cost Per Claim

$665.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carboline derivative and PHOSPHODIESTERASE 5 INHIBITOR that is used primarily to treat ERECTILE DYSFUNCTION; BENIGN PROSTATIC HYPERPLASIA and PRIMARY PULMONARY HYPERTENSION.

Therapeutic Applications

Tadalafil is used to treat high blood pressure in the lungs (pulmonary hypertension). It works by relaxing and widening the blood vessels in your lungs which allows the blood to flow more easily. Decreasing high blood pressure in the lungs allows your heart and lungs to work better and improves your ability to exercise.

Terbutaline Sulfate

Generic Formulation: Terbutaline SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 16.0
Days Supply 405
NV State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$464.11

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.

Therapeutic Applications

Terbutaline is used to treat wheezing and shortness of breath from lung problems (such as asthma, chronic obstructive pulmonary disease-COPD, bronchitis, emphysema). Terbutaline belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 218
30-Day Fills 280.0
Days Supply 8,384
NV State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills77.1
Peer Average Days Supply2,309
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 296.4% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $191,315.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$877.59

State Avg Cost Per Claim

$899.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Uptravi

Generic Formulation: SelexipagSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 42
30-Day Fills 44.0
Days Supply 1,309
NV State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.9
Peer Average Days Supply782
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 61.5% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,026,749.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$24,446.41

State Avg Cost Per Claim

$21,674.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Selexipag is used to treat high blood pressure in the lungs (pulmonary arterial hypertension-PAH). It is used to help slow down worsening of PAH and to decrease the chance of needing treatment in a hospital. Selexipag works by making it easier for blood to flow through the arteries in your lungs. This effect helps increase your ability to exercise.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 71
30-Day Fills 78.9
Days Supply 1,779
NV State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills34.6
Peer Average Days Supply866
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 153.6% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,734.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$80.77

State Avg Cost Per Claim

$82.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Wixela Inhub

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 29
30-Day Fills 33.0
Days Supply 990
NV State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills32.3
Peer Average Days Supply969
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 45.0% more claims than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,941.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$239.35

State Avg Cost Per Claim

$293.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Zemaira

Generic Formulation: Alpha-1-Proteinase InhibitorSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
NV State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills14.0
Peer Average Days Supply392
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $199,244.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,603.71

State Avg Cost Per Claim

$16,709.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Plasma glycoprotein member of the serpin superfamily which inhibits TRYPSIN; NEUTROPHIL ELASTASE; and other PROTEOLYTIC ENZYMES.

Therapeutic Applications

This medication is used to treat lung problems (emphysema) caused by a certain inherited disease (alpha-1-proteinase inhibitor deficiency). In people with this condition, lung damage is caused by elastase, a natural substance that the body needs to kill bacteria in the lungs. Normally, a protein (alpha-1-proteinase inhibitor) stops elastase from working when it is no longer needed. However, in people who do not make enough of this protein, elastase does not stop working and damages the lungs. This medication replaces the missing alpha-1-proteinase inhibitor and helps to prevent further lung damage.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like NARESH P SINGH MD provides transparency into local medical care patterns within Las Vegas, NV.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.